Depleting circulating galectin-3 with therapeutic apheresis: a noveltreatment for sepsis/AKI - otoliths ("ear stones") of RAY-finned fish and the homologous otoconia ("ear dust") of tetrapods are…

Ended Project Grant Awarded Last action

Award ID
R44GM130227
Recipient
Awarding agency
Obligated
$3,755,454

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Originally
Place of performance
California, USA

Award details come from USAspending.gov.

Description

Depleting circulating galectin-3 with therapeutic apheresis: a noveltreatment for sepsis/AKI - otoliths ("ear stones") of RAY-finned fish and the homologous otoconia ("ear dust") of tetrapods are acellular accretions of protein and more than 95% calcium carbonate that often display strikingly elaborate shapes. They convey linear accelerations to sensory hair cells in the utricle, saccule, and lagena and are, therefore, essential components of the vestibular apparatus. They also are involved in one of the most common human balance disorders, benign paroxysmal positional vertigo, in which otoconia are displaced into the semicircular canals. The growth and accumulation of otoliths and otoconia precisely matches their underlying sensory maculae; however, we know very little about the mechanism that regulate this process. Studies of other biominerals suggest that the constituent proteins play critical roles. One class of proteins, the large and insoluble framework proteins, form a matrix for the biomineral to grow in; their local secretion determines the site of morphogenesis. A second class, the highly charged control proteins, interact with the ions and promote or inhibit nucleation or the growth of specific crystallographic faces, thus determining the biomineral's shape. Unfortunately, one cannot test this model because the identities of most of the proteins in otoliths and otoconia are unknown. We intend to remedy this situtation by taking advantage of the unique combination of experimental approaches possible with the zebrafish, danio rerio. We will identify its otolith proteins by sequencing peptides and mining its genome assembly; we will examine if the proteins' expression patterns correlate with the sites of otolith formation; and we will probe the proteins' function by manipulating their expression and analyzing mutants with otolith defects. We will learn from these experiments whether the formation of otoliths and otoconia is governed by the same fundamental principles as that of other biominerals. For future studies of the physiology and pathology of their morphogenesis, we will have developed molecular probes and learned the targets of regulation.

Transactions

Action Obligated Date
Amendment -$0
Amendment $990,810
Amendment $0
Amendment $0
Amendment $691,161
Amendment $691,161
Amendment $691,161
Original award $691,161

Quick answers

Who received award R44GM130227?

R44GM130227 was awarded to Eliaz Therapeutics, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2018.

How much is award R44GM130227 worth?

$3,755,454 has been obligated on R44GM130227.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award